Format

Send to

Choose Destination
Anticancer Res. 2015 Apr;35(4):2411-5.

Src kinase-associated phosphoprotein2 expression is associated with poor prognosis in non-small cell lung cancer.

Author information

1
Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan.
2
Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan bori45@gunmau.ac.jp.

Abstract

BACKGROUND/AIM:

Non-small cell lung cancer (NSCLC) is among the leading causes of cancer-related deaths worldwide. In certain human cancer types, Src is associated with cancer progression and refractory cancer. To improve the prognoses of NSCLC patients, we evaluated Src kinase-associated phosphoprotein 2 (SKAP2), a factor associated with integrin-stimulated cytoskeletal rearrangement, as a new therapeutic target.

MATERIALS AND METHODS:

We performed immunohistochemistry for SKAP2 in 99 NSCLC samples and evaluated the relationship between SKAP2 expression, clinicopathological factors and prognosis.

RESULTS:

Higher SKAP2 expression was detected in cancerous tissues and was predominantly expressed in the cytoplasm. Elevated SKAP2 expression levels were associated with poor prognosis (p=0.007) and shorter survival time after recurrence (p=0.035). High SKAP2 expression was an independent prognostic factor in NSCLC patients (p=0.027).

CONCLUSION:

High SKAP2 expression levels in NSCLC tissues could be a powerful biomarker of poor prognosis. Therefore, SKAP2 is a promising candidate molecular target for NSCLC treatment.

KEYWORDS:

SKAP2; Src; actin assembly; lung cancer

PMID:
25862907
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center